Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.4K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.4K
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

4.3K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
4.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

299
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
299
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

234
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
234
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

431
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
431
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

302
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
302

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Cost-Effectiveness of Recombinant Zoster Vaccine (Shingrix) in US Adults Aged ≥50 Years.

The American journal of medicine·2026
Same author

Need for More HIV-Trained Pharmacists due to Unmet Needs and Expanding Opportunities: An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea.

The Annals of pharmacotherapy·2026
Same author

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.

Diabetes, obesity & metabolism·2026
Same author

What constitutes high risk for venous thromboembolism? Determining an appropriate threshold to initiate prophylaxis.

Journal of thrombosis and haemostasis : JTH·2026

Related Experiment Video

Updated: Nov 19, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.2K

Navigating changes in Clostridioides difficile prevention and treatment.

Spencer H Durham1, Phuc Le2, Angela T Cassano3

  • 1BCPS, BCIDP, Auburn University Harrison School of Pharmacy, Auburn, AL.

Journal of Managed Care & Specialty Pharmacy
|February 3, 2021
PubMed
Summary
This summary is machine-generated.

Clostridioides difficile infections (CDI) are a growing concern, with new treatments and a better understanding of the gut microbiome. Cost-effectiveness evaluations are crucial for managing these infections and guiding clinical decisions.

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.4K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.9K

Related Experiment Videos

Last Updated: Nov 19, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.2K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.4K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.9K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacoeconomics

Background:

  • Clostridioides difficile infections (CDI) represent a significant healthcare challenge, with increasing incidence and severity.
  • Recurrent CDI affects approximately 20% of patients, highlighting the need for effective prevention and treatment strategies.
  • Emergence of hypervirulent strains necessitates updated approaches to CDI management.

Purpose of the Study:

  • To review updated guidelines for CDI prevention and treatment.
  • To evaluate the role of the gut microbiome in CDI pathogenesis and recurrence.
  • To summarize the cost-effectiveness of various CDI treatment options.

Main Methods:

  • Qualitative review and evaluation of existing literature on CDI treatments.
  • Analysis of comparative effectiveness research (CER) data.
  • Assessment of novel therapies in various stages of clinical development.

Main Results:

  • Updated 2017 Infectious Diseases Society of America (IDSA) guidelines recommend oral vancomycin or fidaxomicin for first-time CDI episodes.
  • Fecal microbiota transplant (FMT) is recommended for patients with three or more recurrent CDI episodes.
  • Novel therapies including ridinilazole, SER-109, RBX2660, and a vaccine show promise in early trials.

Conclusions:

  • Cost-effectiveness evaluations are essential for clinical decision-making, especially with newer, more expensive CDI treatments.
  • Understanding the microbiome's role is key to developing innovative strategies for CDI prevention and treatment.
  • Continued research into novel therapeutics and comparative effectiveness is vital for combating CDI.